The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest